Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells.

Cancers (Basel) · 2018 · PMC6116004 · PMID 30060526

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

However, the results of a clinical trial with Tarextumab, an antibody inhibiting NOTCH 2/3, although initially showed a trend towards an improvement of progression-free survival in patients whose tumors expressed elevated levels of NOTCH target genes, failed to confirm this trend in in a larger cohort of patients in the context of a phase II study [ 117 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.